Two pathologies drive the progression of Alzheimer’s disease. Early on, amyloid beta plaques lead the way, but around the time cognitive symptoms arise, tau tangles take over as the driving force and cognition steadily declines. Tracking the course of the disease in individual patients has been challenging because there’s been no easy way to measure […]
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, will receive the 2023 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. Bateman has been chosen to receive the honor for his groundbreaking work in Alzheimer’s research, including the development of plasma […]
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, will receive the 2023 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. Bateman has been chosen to receive the honor for his groundbreaking work in Alzheimer’s research, including the development of plasma […]
Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there’s no easy way to distinguish among people living with any of the primary tauopathies — a group of rare brain diseases marked by rapidly worsening problems with thinking and movement — because the symptoms […]
An idea that has propelled Alzheimer’s research for more than 30 years is approaching its day of reckoning. Scientists are launching a study designed to make or break the hypothesis that Alzheimer’s is caused by a sticky substance called beta-amyloid. The study will give an experimental anti-amyloid drug to people as young as 18 who […]
Carlos Cruchaga, PhD, has received a 2022 Zenith Fellow Award from the Alzheimer’s Association. The annual award is given to scientists who have made significant contributions to the field of Alzheimer’s disease research and are likely to make additional, substantial contributions in the future. Funding attached to the fellowships also helps support high- risk, high-reward projects in […]
A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]
Three experimental blood tests used to identify people in early stages of Alzheimer’s disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine in St. Louis. The study showed that a fourth blood test — the PrecivityAD test, which is commercially available in the […]
A blood test developed at Washington University School of Medicine in St. Louis has proven highly accurate in detecting early signs of Alzheimer’s disease in a study involving nearly 500 patients from across three continents, providing further evidence that the test should be considered for routine screening and diagnosis. The study is available in the […]
Longtime St. Louis benefactor Joanne Knight has committed up to $11.5 million to Washington University School of Medicine in St. Louis to support an innovative clinical trial aimed at preventing Alzheimer’s disease by treating people before the first signs of the illness appear in the brain. In recognition of this gift and the Knight family’s […]
Washington University School of Medicine in St. Louis is launching an international clinical trial aimed at preventing Alzheimer’s disease in people genetically destined to develop the illness at a young age. Unlike most other Alzheimer’s prevention trials, this one will enroll people before the disease has taken hold – up to 25 years before the […]
Moving innovations out of the so-called ivory tower and into the public domain holds enormous power to treat disease and improve quality of life. But while academic researchers and physicians may imagine promising clinical solutions, some are unprepared to navigate commercialization: pitching themselves, attracting investors, wrangling with intellectual property law, designing rigorous proof-of-concept studies, locating […]
Researchers leading a worldwide clinical trial aimed at finding treatments for Alzheimer’s disease are modifying an arm of the trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The trial – known as the Tau Next Generation Trial (Tau NexGen) – originally was announced with a focus on drugs that […]
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU). These results led the trial leaders to offer the drug, […]
Clinical scientists at Washington University School of Medicine in St. Louis and University College London are collaborating with pharmaceutical companies AbbVie, Biogen, Bristol Myers Squibb and Roche to investigate the role of neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease. NfL is a protein […]
A worldwide clinical trial aimed at finding treatments for Alzheimer’s disease has expanded to include investigational drugs targeting a harmful form of the brain protein tau. The trial, known as the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in St. Louis, launched in 2012 as the first […]
Neurologist Randall J. Bateman, MD, virologist and immunologist Michael S. Diamond, MD, PhD, and microbiologist Scott Hultgren — all faculty members at Washington University School of Medicine in St. Louis — have been named fellows of the National Academy of Inventors, the highest professional distinction accorded solely to academic inventors. They are among 175 new fellows elected this year […]
A novel form of an Alzheimer’s protein found in the fluid that surrounds the brain and spinal cord indicates what stage of the disease a person is in, and tracks with tangles of tau protein in the brain, according to a study from researchers at Washington University School of Medicine in St. Louis. Tau tangles […]
Deanna M. Barch, PhD, an expert in cognitive and language deficits in psychological disorders, and Randall J. Bateman, MD, a leading Alzheimer’s disease researcher, have been elected to the National Academy of Medicine, a part of the National Academy of Sciences. Membership in the organization is extended to those who have demonstrated outstanding professional achievement and commitment […]
Two decades or more before symptoms arise, plaques of a sticky protein called amyloid begin forming in the brains of people later diagnosed with Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have shown that levels of a specific protein in the blood rise as amyloid plaques form in the brain. […]
Alzheimer’s disease is the most common form of dementia, affecting more than 5 million people in the U.S., but doctors have limited advice on how to protect against it. The disease develops silently in the brain for two decades or more before people begin showing the characteristic signs of forgetfulness and confusion. Understanding that silent […]
An international clinical trial evaluating whether two investigational drugs can slow memory loss and cognitive decline in people in the early stages of a rare, inherited form of Alzheimer’s disease has yielded disappointing results, an initial analysis of the data has shown. However, the researchers continue to explore data from the trial’s cognitive and clinical […]
For more than a decade, Washington University School of Medicine in St. Louis has led an international effort to better understand Alzheimer’s disease by studying people with rare genetic mutations that cause the disease to develop in their 50s, 40s or even 30s. The researchers have shown that the disease begins developing two decades or […]
A major international Alzheimer’s disease research initiative will open five new sites in Latin America to help researchers understand the development of early-onset Alzheimer’s in Latino populations. For more than a decade, the Dominantly Inherited Alzheimer Network (DIAN) – funded in large part by the National Institutes of Health (NIH) and led by Washington University School of […]
Up to two decades before people develop the characteristic memory loss and confusion of Alzheimer’s disease, damaging clumps of protein start to build up in their brains. Now, a blood test to detect such early brain changes has moved one step closer to clinical use. Researchers from Washington University School of Medicine in St. Louis […]
For decades, researchers have sought a blood test for beta amyloid, the protein that is a hallmark of Alzheimer’s disease. Several groups and companies have made progress, and on Thursday, scientists at Washington University in St. Louis reported that they had devised the most sensitive blood test yet. The test will not be available for […]
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, has been awarded the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases. He will receive the award May 6 at the American Academy of Neurology’s annual meeting in Philadelphia. Sometimes […]
Doctors may soon be able to predict, prevent Alzheimer’s disease From the WashU Outlook Magazine… Caring for an aging relative with Alzheimer’s disease, watching memories slowly slip away, is an exhausting and heartbreaking ordeal. For those with the condition, modern medicine can offer little in the way of treatment as the disease inexorably strips away […]
Targeting tau production may lead to treatment From the WashU Newsroom… It’s a paradox of Alzheimer’s disease: Plaques of the sticky protein amyloid beta are the most characteristic sign in the brain of the deadly neurodegenerative disease. However, many older people have such plaques in their brains but do not have dementia. The memory loss […]
Study shows sleepless night taxes brain’s waste-disposal abilities From the WashU Newsroom… Have you resolved to take better care of yourself in the new year? Here’s a relatively painless way to do it: Catch a few more zzz’s every night. A third of American adults don’t get enough sleep, according to the Centers for Disease Control […]
Why move from current standards of patient care to a more personalized approach to treatment? Experts at the School of Medicine describe today’s medical landscape as they plan for the care — and cures — of the future. From the WashU Newsroom… Of the top-grossing domestic movies of 2017 to date, three of the Top 5 […]
